Neuroderm Ltd (NASDAQ:NDRM): Matt Sirovich And Jeremy Mindich’s Scopia Capital filed an amended 13D.
You can check out Scopia Capital’s latest holdings and filings here.
Please follow Scopia Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Scopia Capital or update its stock holdings.
Follow Matt Sirovich's Scopia Capital
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Scopia Capital Management | 0 | 205,358 | 0 | 205,358 | 205,358 | 0.78% |
| Scopia Management, Inc | 0 | 205,358 | 0 | 205,358 | 205,358 | 0.78% |
| Matthew Sirovich | 0 | 205,358 | 0 | 205,358 | 205,358 | 0.78% |
| Jeremy Mindich | 0 | 205,358 | 0 | 205,358 | 205,358 | 0.78% |
Follow Matt Sirovich's Scopia Capital
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 11 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
| NeuroDerm Ltd. |
| (Name of Issuer) |
| Ordinary Shares, par value NIS 0.01 per share |
| (Title of Class of Securities) |
| M74231107 |
| (CUSIP Number) |
| August 31, 2017 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:
[X] Rule
13d-1(b)
[_] Rule
13d-1(c)
[_] Rule
13d-1(d)
_________
| (1) | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The
information required in the remainder of this cover page shall not be deemed to be “filed’ for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 11 – SEC Filing
| CUSIP No. | M74231107 |
| 1. | NAME OF REPORTING PERSONS: Scopia Capital Management LP | |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | |
| (a) [_] | ||
| (b) [_] | ||
| 3. | SEC USE ONLY | |
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
| Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | ||
| 5. | SOLE VOTING POWER | |
| 0 | ||
| 6. | SHARED VOTING POWER | |
| 205,358 | ||
| 7. | SOLE DISPOSITIVE POWER | |
| 0 | ||
| 8. | SHARED DISPOSITIVE POWER | |
| 205,358 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
| 205,358 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | |
| [_] | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |
| 0.78% | ||
| 12. | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | |
| PN, IA | ||
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 11 – SEC Filing
| CUSIP No. | M74231107 |
| 1. | NAME OF REPORTING PERSONS: Scopia Management, Inc. | |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | |
| (a) [_] | ||
| (b) [_] | ||
| 3. | SEC USE ONLY | |
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
| New York | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | ||
| 5. | SOLE VOTING POWER | |
| 0 | ||
| 6. | SHARED VOTING POWER | |
| 205,358 | ||
| 7. | SOLE DISPOSITIVE POWER | |
| 0 | ||
| 8. | SHARED DISPOSITIVE POWER | |
| 205,358 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
| 205,358 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | |
| [_] | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |
| 0.78% | ||
| 12. | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | |
| CO, HC | ||
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 11 – SEC Filing
| CUSIP No. | M74231107 |
| 1. | NAME OF REPORTING PERSONS: Matthew Sirovich | |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | |
| (a) [_] | ||
| (b) [_] | ||
| 3. | SEC USE ONLY | |
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
| United States | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | ||
| 5. | SOLE VOTING POWER | |
| 0 | ||
| 6. | SHARED VOTING POWER | |
| 205,358 | ||
| 7. | SOLE DISPOSITIVE POWER | |
| 0 | ||
| 8. | SHARED DISPOSITIVE POWER | |
| 205,358 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
| 205,358 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | |
| [_] | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |
| 0.78% | ||
| 12. | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | |
| IN, HC | ||
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 11 – SEC Filing
| CUSIP No. | M74231107 |
| 1. | NAME OF REPORTING PERSONS: Jeremy Mindich | |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | |
| (a) [_] | ||
| (b) [_] | ||
| 3. | SEC USE ONLY | |
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
| United States | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | ||
| 5. | SOLE VOTING POWER | |
| 0 | ||
| 6. | SHARED VOTING POWER | |
| 205,358 | ||
| 7. | SOLE DISPOSITIVE POWER | |
| 0 | ||
| 8. | SHARED DISPOSITIVE POWER | |
| 205,358 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
| 205,358 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | |
| [_] | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |
| 0.78% | ||
| 12. | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | |
| IN, HC | ||
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 11 – SEC Filing
| CUSIP No. | M74231107 |
| Item 1. | (a). | Name of Issuer: | |
| NeuroDerm Ltd. |
| (b). | Address of Issuer’s Principal Executive Offices: | ||
| Ruhrberg Science Building 3 Pekeris Street Rehovot 7670212, Israel |
| Item 2. | (a). | Name of Person Filing: | |
| Scopia Capital Management LP Scopia Management, Inc. Matthew Sirovich Jeremy Mindich |
| (b). | Address or Principal Business Office or, if None, Residence: | ||
| Scopia Capital Management LP 152 West 57th Street, 33rd Floor New York, NY 10019 Scopia Management, Inc. 152 West 57th Street, 33rd Floor New York, NY 10019 |
| (c). | Citizenship: | ||
| Scopia Capital Management LP is a Delaware limited partnership Scopia Management, Inc. is a New York Corporation Matthew Sirovich is a United States citizen Jeremy Mindich is a United States citizen |
| (d). | Title of Class of Securities: | ||
| Ordinary Shares, par value NIS 0.01 per share |
| (e). | CUSIP Number: | ||
| M74231107 |
| Item 3. | If this statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a |
| (a) | [_] | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). | |
| (b) | [_] | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). | |
| (c) | [_] | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). | |
| (d) | [_] | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). | |
| (e) | [X] | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); | |
| (f) | [_] | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); | |
| (g) | [X] | A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); | |
| (h) | [_] | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813); | |
| (i) | [_] | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |
| (j) | [_] | A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); | |
| (k) | [_] | Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: |
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 7 of 11 – SEC Filing
| CUSIP No. | M74231107 |
| Item 4. | Ownership. |
| Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. | |
| Scopia Capital Management LP |
| (a) | Amount beneficially owned: | |
| 205,358 |
| (b) | Percent of class: | |
| 0.78% |
| (c) | Number of shares as to which the person has: |
| (i) | Sole power to vote or to direct the vote | 0 | , | ||
| (ii) | Shared power to vote or to direct the vote | 205,358 | |||
| (iii) | Sole power to dispose or to direct the disposition of | 0 | , | ||
| (iv) | Shared power to dispose or to direct the disposition of | 205,358 |
| Scopia Management, Inc. |
| (a) | Amount beneficially owned: | |
| 205,358 |
| (b) | Percent of class: | |
| 0.78% |
| (c) | Number of shares as to which the person has: |
| (i) | Sole power to vote or to direct the vote | 0 | |||
| (ii) | Shared power to vote or to direct the vote | 205,358 | |||
| (iii) | Sole power to dispose or to direct the disposition of | 0 | |||
| (iv) | Shared power to dispose or to direct the disposition of | 205,358 |
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 8 of 11 – SEC Filing
| Matthew Sirovich |
| (a) | Amount beneficially owned: | |
| 205,358 |
| (b) | Percent of class: | |
| 0.78% |
| (c) | Number of shares as to which the person has: | |
| (i) | Sole power to vote or to direct the vote | 0 | , | ||
| (ii) | Shared power to vote or to direct the vote | 205,358 | |||
| (iii) | Sole power to dispose or to direct the disposition of | 0 | , | ||
| (iv) | Shared power to dispose or to direct the disposition of | 205,358 |
| Jeremy Mindich |
| (a) | Amount beneficially owned: | |
| 205,358 |
| (b) | Percent of class: | |
| 0.78% |
| (c) | Number of shares as to which the person has: |
| (i) | Sole power to vote or to direct the vote | 0 | , | ||
| (ii) | Shared power to vote or to direct the vote | 205,358 | |||
| (iii) | Sole power to dispose or to direct the disposition of | 0 | , | ||
| (iv) | Shared power to dispose or to direct the disposition of | 205,358 |
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 9 of 11 – SEC Filing
| Item 5. | Ownership of Five Percent or Less of a Class. |
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]. | |
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
| If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. | |
| All securities reported in this Schedule 13G amendment are directly held by advisory clients of Scopia Capital Management LP. None of such advisory clients individually holds more than 5% of the Issuer’s outstanding shares. | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
| If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b) (1) (ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. | |
| N/A | |
| Item 8. | Identification and Classification of Members of the Group. |
| If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §§ 240.13d-1(c) or §§ 240.13d-1(d), attach an exhibit stating the identity of each member of the group. | |
| N/A | |
| Item 9. | Notice of Dissolution of Group. |
| Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. |
| N/A | |
| Item 10. | Certification. |
| By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. |
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 10 of 11 – SEC Filing
SIGNATURE
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| September 11, 2017 | |
| (Date) | |
| SCOPIA CAPITAL MANAGEMENT LP | |
| By: /s/ Samantha Nasello | |
| Name: Samantha Nasello | |
| Title: CCO | |
| Scopia Management, Inc. | |
| By: /s/ Aaron Morse | |
| Name: Aaron Morse | |
| Title: Vice President | |
| By: /s/ Matthew Sirovich | |
| Name: Matthew Sirovich | |
| By: /s/ Jeremy Mindich | |
| Name: Jeremy Mindich | |
Note. Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to
be sent.
Attention. Intentional misstatements or omissions of
fact constitute Federal criminal violations (see 18 U.S.C. 1001).
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 11 of 11 – SEC Filing
EXHIBIT INDEX
| 99.1 | Joint Filing Agreement, dated as of September 11, 2017, by and among the Reporting Persons |
Follow Neuroderm Ltd.
Follow Neuroderm Ltd.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
